With the U.S. declaration of a nationwide well being emergency the TPOXX drug may quickly be extra extensively accessible below an EUA. The corporate itself doesn’t have its personal manufacturing amenities however as a substitute depends on third-party manufacturing sources. This implies the corporate’s CAP X may be very low and so they can scale up manufacturing if required.
If the monkey pox outbreak warrants the corporate can produce as much as 500,000 programs a 12 months with the present capability. In tablet kind, the drug is taken over a interval of two weeks and this can be a course. The worth for every course for worldwide clients Is $900-$1000 per course. Within the US it’s $300-$400. Pricing differs relying on the dimensions of the order. Ought to the corporate ship 500,000 programs in a single 12 months it’s income from Tecovirimat can be $500 million in that 12 months. Income (TTM) was 139.4 million as per final reporting, so the expansion potential for the corporate and its share value is important. Particularly if ( as is now predicted by many well being professionals) Monkeypox turns into endemic globally.
Hyperlink to SIGA Applied sciences earnings report.
https://investor.siga.com/news-releases/news-release-details/siga-reports-financial-results-three-and-six-months-ended-june-0
